In the last trading session, 1.33 million shares of the Coherus Oncology Inc (NASDAQ:CHRS) were traded, and its beta was 0.87. Most recently the company’s share price was $0.81, and it changed around $0.06 or 8.84% from the last close, which brings the market valuation of the company to $94.16M. CHRS currently trades at a discount to its 52-week high of $2.43, offering almost -200.0% off that amount. The share price’s 52-week low was $0.66, which indicates that the current value has risen by an impressive 18.52% since then. We note from Coherus Oncology Inc’s average daily trading volume that its 10-day average is 1.26 million shares, with the 3-month average coming to 1.51 million.
Coherus Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended CHRS as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
Coherus Oncology Inc (NASDAQ:CHRS) trade information
Instantly CHRS has showed a green trend with a performance of 8.84% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.8200 on recent trading dayincreased the stock’s daily price by 1.22%. The company’s shares are currently down -41.57% year-to-date, but still up 11.06% over the last five days. On the other hand, Coherus Oncology Inc (NASDAQ:CHRS) is 0.81% up in the 30-day period. We can see from the shorts that 31.94 million shares have been sold at a short interest cover period of 21.85 day(s).
The consensus price target as assigned by Wall Street analysts is $1.05, which translates to bulls needing to increase their stock price by 22.86% from its current value. Analyst projections state that CHRS is forecast to be at a low of $1.05 and a high of $1.05.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -27.36%.
CHRS Dividends
Coherus Oncology Inc’s next quarterly earnings report is expected to be released on 2025-May-12.
Coherus Oncology Inc (NASDAQ:CHRS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.54% of Coherus Oncology Inc shares, and 54.00% of them are in the hands of institutional investors. The stock currently has a share float of 57.77%. Coherus Oncology Inc stock is held by 154.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 10.2356% of the shares, which is about 11.75 million shares worth $20.33 million.
VANGUARD GROUP INC, with 9.2339% or 10.6 million shares worth $18.34 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Mar 31, 2025 . The former held 3.43 shares worth $2.79 million, making up 2.96% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 2.74 shares worth around $2.23 million, which represents about 2.37% of the total shares outstanding.
